BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones TC. Call for a new approach to the process of clinical trials and drug registration. BMJ 2001;322:920-3. [PMID: 11302912 DOI: 10.1136/bmj.322.7291.920] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Jones TC. A call to restructure the drug development process: government over-regulation and non-innovative late stage (Phase III) clinical trials are major obstacles to advances in health care. Sci Eng Ethics 2005;11:575-87. [PMID: 16279756 DOI: 10.1007/s11948-005-0027-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials: Statistical evaluation of surrogate endpoints. Biom J 2016;58:104-32. [DOI: 10.1002/bimj.201400049] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
3 Fallico M, Maugeri A, Lotery A, Longo A, Bonfiglio V, Russo A, Avitabile T, Furino C, Cennamo G, Barchitta M, Agodi A, Marolo P, Ventre L, Caselgrandi P, Reibaldi M. Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience. Sci Rep 2021;11:4800. [PMID: 33637841 DOI: 10.1038/s41598-021-84362-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mcmahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidem Drug Safe 2003;12:551-8. [DOI: 10.1002/pds.883] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 3.9] [Reference Citation Analysis]
5 Alonso A, Molenberghs G. Surrogate end points: hopes and perils. Expert Review of Pharmacoeconomics & Outcomes Research 2014;8:255-9. [DOI: 10.1586/14737167.8.3.255] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
6 Santos PM, Oliveira MG, Costa LA, Noblat L. [Drug-related clinical research--a practical opportunity for the hospital pharmacist]. Farm Hosp 2006;30:124-9. [PMID: 16796427 DOI: 10.1016/s1130-6343(06)73958-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Garattini S, Bertele' V. New approach to clinical trials and drug registration. Author's suggestions for drug approval are questionable. BMJ 2001;323:341. [PMID: 11548679 DOI: 10.1136/bmj.323.7308.341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
8 Molenberghs G, Burzykowski T, Alonso A, Assam P, Tilahun A, Buyse M. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. Stat Methods Med Res 2010;19:205-36. [PMID: 19608602 DOI: 10.1177/0962280209105015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
9 Vogelberg C. Preschool children with persistent asthmatic symptoms. Ther Clin Risk Manag 2019;15:451-60. [PMID: 30936707 DOI: 10.2147/TCRM.S170979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
10 Ioannidis JP, Polycarpou A, Ntais C, Pavlidis N. Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time. Eur J Cancer 2003;39:2278-87. [PMID: 14556918 DOI: 10.1016/s0959-8049(03)00571-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]